Α5IA

α 5 IA (LS-193,268) is a nootropic drug invented in 2004 by a team working for Merck, Sharp and Dohme, which acts as a subtype-selective inverse agonist at the benzodiazepine binding site on the GABA A receptor.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

α 5 IA (LS-193,268) is a nootropic drug invented in 2004 by a team working for Merck, Sharp and Dohme, which acts as a subtype-selective inverse agonist at the benzodiazepine binding site on the GABA A receptor. It binds to α 1 , α 2 , α 3 and α 5 -containing subtypes, with functional selectivity for α 5 -containing subtypes.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1359574986 under CC BY-SA 4.0; modifications have been made.

Provenance

snapshot enwiki-001359574986 · captured 1781566205.0 · version history

Cite this page as: encyclopegia.org, “Α5IA”, snapshot enwiki-001359574986. https://encyclopegia.org/a/5ia

Sources cited in this revision

No external citation was extracted for this revision. That is a statement about the source, not a claim that none exists.